Evidence map›Paper›PMID 38911919›Full record

ArticleClinical case reports2024

Sulin Luo, Pengpeng Yan, Xingxia Wang, Xue Ren, Ke Sun, Luying Guo, Junhao Lv, Xinhui Su, Kui Zhao, Jianghua Chen and 1 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Infection and drug resistance · 2025
    Article
  3. Clinical case reports · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Sulin LuoKidney Disease Center, The First Affiliated Hospital, School of Medicine Zhejiang University Hangzhou China.
Pengpeng YanKidney Disease Center, The First Affiliated Hospital, School of Medicine Zhejiang University Hangzhou China.
Xingxia WangKidney Disease Center, The First Affiliated Hospital, School of Medicine Zhejiang University Hangzhou China.
Xue RenKidney Disease Center, The First Affiliated Hospital, School of Medicine Zhejiang University Hangzhou China.
Ke SunDepartment of Pathology, First Affiliated Hospital, School of Medicine Zhejiang University Hangzhou China.
Luying GuoKidney Disease Center, The First Affiliated Hospital, School of Medicine Zhejiang University Hangzhou China.
Junhao LvKidney Disease Center, The First Affiliated Hospital, School of Medicine Zhejiang University Hangzhou China.
Xinhui SuDepartment of Nuclear Medicine, PET Centre, First Affiliated Hospital, School of Medicine Zhejiang University Hangzhou China.
Kui ZhaoDepartment of Nuclear Medicine, PET Centre, First Affiliated Hospital, School of Medicine Zhejiang University Hangzhou China.
Jianghua ChenKidney Disease Center, The First Affiliated Hospital, School of Medicine Zhejiang University Hangzhou China.
Rending WangKidney Disease Center, The First Affiliated Hospital, School of Medicine Zhejiang University Hangzhou China.ORCID https://orcid.org/0000-0002-2063-8533

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Key Clinical Message: In addition to post-transplant lymphoproliferative disorders, it is necessary to be alert to the drug-resistant bacteria or fungal infection, especially Abstract:

Indexed as

kidney transplantmetagenomic next‐generation sequencingpost‐transplant lymphoproliferative disordersTalaromyces marneffei

Identifiers

PMID38911919
PMCPMC11192592

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.